Suppr超能文献

棒状尼达尼布纳米晶体通过多种肠吸收途径提高了口服生物利用度。

Rod-shaped nintedanib nanocrystals improved oral bioavailability through multiple intestinal absorption pathways.

机构信息

Department of Pharmaceutics, College of Pharmacy, Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang 110016, China; Luye Pharmaceutical Group, Yantai,China.

Department of Pharmaceutics, College of Pharmacy, Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang 110016, China.

出版信息

Eur J Pharm Sci. 2022 Jan 1;168:106047. doi: 10.1016/j.ejps.2021.106047. Epub 2021 Oct 20.

Abstract

Nintedanib (BIBF) is a biopharmaceutical classification system II (BCS II) drug that has a good therapeutic effect for the treatment of nonsmall cell lung cancer; however, it shows poor oral bioavailability due to low dissolution and intestinal absorption. This study aims to fabricate rod-shaped nanocrystals to enhance oral bioavailability by improving the dissolution and absorption of BIBF in the intestine. By prescription screening, BIBF nanocrystals (BIBF-NCs) with a particle size of 325.30 ± 1.03 nm and zeta potential of 32.70 ± 1.24 mV were fabricated by an antisolvent precipitation-ultrasound approach with a stabilizer of sodium carboxyl methyl cellulose (CMC-Na). BIBF-NCs exhibited a rod-shaped morphology by transmission electron microscopy (TEM). The results of powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) showed that the crystal form of BIBF in BIBF-NCs was altered. The BIBF-NCs remarkably improved the saturation solubility and dissolution of BIBF compared with BIBF powder. According to the results of in situ single-pass intestinal perfusion (SPIP), BIBF-NCs showed improved absorption and membrane permeability, with K and P values in the jejunum of 0.21 ± 0.01 min and (4.34 ± 0.11) × 10 cm/min, respectively. Further, the K and P values of BIBF-NCs were all reduced significantly after the addition of inhibitors colchicine, chlorpromazine and indomethacin, which demonstrated that BIBF-NCs could be absorbed by endocytosis mediated by caveolae and clathrin and micropinocytosis in the intestine. The cell evaluation results showed that BIBF-NCs could be taken up by macrophages and transported from Caco-2 monolayers. The in vivo pharmacokinetic results showed that the bioavailability of the BIBF-NCs was 2.51-fold higher than that of the BIBF solution (BIBF-Sol) after oral administration with a longer T (4.50 ± 1.00 h vs. 2.60 ± 1.92 h). In summary, rod-shaped BIBF-NCs could significantly improve oral bioavailability through multiple intestinal absorption pathways.

摘要

尼达尼布(BIBF)是一种生物制药分类系统 II(BCS II)药物,对治疗非小细胞肺癌有很好的疗效;然而,由于低溶解和肠道吸收,其口服生物利用度较差。本研究旨在通过改善 BIBF 在肠道中的溶解和吸收来制备棒状纳米晶体以提高口服生物利用度。通过处方筛选,采用抗溶剂沉淀-超声法,以羧甲基纤维素钠(CMC-Na)为稳定剂,制备出粒径为 325.30±1.03nm、Zeta 电位为 32.70±1.24mV 的 BIBF 纳米晶体(BIBF-NCs)。透射电子显微镜(TEM)显示 BIBF-NCs 呈棒状形态。粉末 X 射线衍射(PXRD)和差示扫描量热法(DSC)的结果表明 BIBF-NCs 中 BIBF 的晶体形式发生了变化。BIBF-NCs 显著提高了 BIBF 的饱和溶解度和溶解度,与 BIBF 粉末相比。根据原位单次通过肠灌流(SPIP)的结果,BIBF-NCs 显示出改善的吸收和膜通透性,空肠中的 K 和 P 值分别为 0.21±0.01min 和(4.34±0.11)×10cm/min。此外,在加入秋水仙碱、氯丙嗪和吲哚美辛抑制剂后,BIBF-NCs 的 K 和 P 值均显著降低,这表明 BIBF-NCs 可通过肠内小窝和网格蛋白介导的内吞作用和微胞饮作用吸收。细胞评价结果表明,BIBF-NCs 可被巨噬细胞摄取并从 Caco-2 单层转运。体内药代动力学结果表明,口服 BIBF-NCs 后的生物利用度是 BIBF 溶液(BIBF-Sol)的 2.51 倍,T(4.50±1.00h 比 2.60±1.92h)更长。综上所述,棒状 BIBF-NCs 可通过多种肠道吸收途径显著提高口服生物利用度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验